270 related articles for article (PubMed ID: 29631666)
21. Compounding pharmacy conundrum: "we cannot live without them but we cannot live with them" according to the present paradigm.
Guharoy R; Noviasky J; Haydar Z; Fakih MG; Hartman C
Chest; 2013 Apr; 143(4):896-900. PubMed ID: 23412546
[TBL] [Abstract][Full Text] [Related]
22. Drug safety and efficacy impaired by quality failure.
Ekiert RJ
Pharmazie; 2011 Jun; 66(6):467-9. PubMed ID: 21699091
[TBL] [Abstract][Full Text] [Related]
23. Topical otic drugs in a multi-purpose manufacturing facility: a guide on determination and application of permitted daily exposure (PDE).
Wiesner L; Prause M; Lovsin Barle E
Pharm Dev Technol; 2018 Mar; 23(3):261-264. PubMed ID: 28535123
[TBL] [Abstract][Full Text] [Related]
24. Sterile products: advances and challenges in formulation, manufacturing and regulatory aspects--a regulatory review perspective.
Hussong D
AAPS PharmSciTech; 2010 Sep; 11(3):1482-4. PubMed ID: 20845091
[TBL] [Abstract][Full Text] [Related]
25. Concept of biosimilar products in Jordan.
Haddadin RD
Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079
[TBL] [Abstract][Full Text] [Related]
26. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
World Health Organization
World Health Organ Tech Rep Ser; 2005; 929():1-142, backcover. PubMed ID: 16353684
[TBL] [Abstract][Full Text] [Related]
27. What to consider for a good quality PDE document?
Sehner C; Schwind M; Tuschl G; Lovsin Barle E
Pharm Dev Technol; 2019 Sep; 24(7):803-811. PubMed ID: 30865481
[TBL] [Abstract][Full Text] [Related]
28. Data Integrity-A Study of Current Regulatory Thinking and Action.
Shafiei N; De Montardy R; Rivera-Martinez E
PDA J Pharm Sci Technol; 2015; 69(6):762-70. PubMed ID: 26659106
[TBL] [Abstract][Full Text] [Related]
29. Guidelines for Risk-Based Changeover of Biopharma Multi-Product Facilities.
Lynch R; Barabani D; Bellorado K; Canisius P; Heathcote D; Johnson A; Wyman N; Parry DW
PDA J Pharm Sci Technol; 2018; 72(1):91-103. PubMed ID: 29030526
[TBL] [Abstract][Full Text] [Related]
30. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
Kroes BH
J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
[TBL] [Abstract][Full Text] [Related]
31. Approaches to Quality Risk Management When Using Single-Use Systems in the Manufacture of Biologics.
Ishii-Watabe A; Hirose A; Katori N; Hashii N; Arai S; Awatsu H; Eiza A; Hara Y; Hattori H; Inoue T; Isono T; Iwakura M; Kajihara D; Kasahara N; Matsuda H; Murakami S; Nakagawa T; Okumura T; Omasa T; Takuma S; Terashima I; Tsukahara M; Tsutsui M; Yano T; Kawasaki N
AAPS PharmSciTech; 2015 Oct; 16(5):993-1001. PubMed ID: 26288941
[TBL] [Abstract][Full Text] [Related]
32. Good manufacturing practice for immunological veterinary medicinal products.
Todd JI
Rev Sci Tech; 2007 Apr; 26(1):135-45. PubMed ID: 17633298
[TBL] [Abstract][Full Text] [Related]
33. Good manufacturing practice: the role of local manufacturers and competent authorities.
Tomić S; Filipović Sučić A; Ilić Martinac A
Arh Hig Rada Toksikol; 2010 Dec; 61(4):425-36. PubMed ID: 21183434
[TBL] [Abstract][Full Text] [Related]
34. Identifying and assessing highly hazardous drugs within quality risk management programs.
Sussman RG; Schatz AR; Kimmel TA; Ader A; Naumann BD; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S11-8. PubMed ID: 27267171
[TBL] [Abstract][Full Text] [Related]
35. Current development in regulation of similar biotherapeutic products in Brazil.
Castanheira LG; Barbano DB; Rech N
Biologicals; 2011 Sep; 39(5):308-11. PubMed ID: 21868247
[TBL] [Abstract][Full Text] [Related]
36. [The new norms decreed by the legislative dirrective 91-93 CCE].
Neri M; Palazzo S
Boll Chim Farm; 1998 Feb; 137(2):31-4. PubMed ID: 9595832
[TBL] [Abstract][Full Text] [Related]
37. Elemental impurities in pharmaceutical products adding fuel to the fire.
Maithani M; Raturi R; Sharma P; Gupta V; Bansal P
Regul Toxicol Pharmacol; 2019 Nov; 108():104435. PubMed ID: 31376414
[TBL] [Abstract][Full Text] [Related]
38. How development and manufacturing will need to be structured--heads of development/manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Nepveux K; Sherlock JP; Futran M; Thien M; Krumme M
J Pharm Sci; 2015 Mar; 104(3):850-64. PubMed ID: 25630721
[TBL] [Abstract][Full Text] [Related]
39. Contaminated dietary supplements.
Carvajal R
N Engl J Med; 2010 Jan; 362(3):274; author reply 274. PubMed ID: 20089984
[No Abstract] [Full Text] [Related]
40. Regulators scramble to tighten loopholes after heparin debacle.
Jia H
Nat Biotechnol; 2008 May; 26(5):477-8. PubMed ID: 18464756
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
